However, for patients with breast tumors expressing low levels of HR, categorically defined as 1–9% of ER or 1–20% of PgR, it is recommended to add more aggressive treatments such as chemotherapy, with endocrine therapy, for the oncologic safety of the patients [15]. The gene discussed is ESR1; the disease is breast neoplasm.